arrow
P

Phillip Scheinberg

hospital a beneficencia portuguesa de sao paulo
H指数:53
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)

多组学验证骨髓增生异常综合征(MDS)分子分类的临床相关性

2026-07-280
OAAI
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia

美国血液学学会2026年严重获得性再生障碍性贫血的诊断和管理指南

2026-04-010
OAAI
Criteria for referring pediatric and adult patients with hematological diseases to palliative care: Consensus of the Brazilian Association of Hematology, hemotherapy and cell therapy (2025)

巴西血液学、输血医学和细胞治疗协会(2025年)关于将儿科和成人血液病患者转诊至姑息治疗的指征共识

2026-04-010
OAAI
A Distinct Intestinal Domination Fingerprint in Patients Undergoing Allo-HSCT: Dynamics, Predictors and Implications on Clinical Outcomes

异基因造血干细胞移植患者的独特肠道优势指纹:动态变化、预测因素及对临床结局的影响

2026-03-030
OAAI
Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis

C5抑制剂Crovalimab在阵发性夜间血红蛋白尿症患者中的有效性与安全性:一项系统评价和Meta分析

2025-11-010
PRE
Unraveling the Intestinal Microbiota Conundrum in Allogeneic Hematopoietic Stem Cell Transplantation: Fingerprints, Clinical Implications and Future Directions

解析异基因造血干细胞移植中肠道微生物组的谜团:特征、临床意义及未来方向

2025-10-010
OAAI
Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies

管理阵发性睡眠性血红蛋白尿症患者中的短暂免疫复合物反应:COMMODORE 1和2研究的临床观察

2025-09-170
OA
Incidence and associated factors with atrial fibrillation in patients with transthyretin amyloidosis cardiomyopathy: Insights from the multicenter REACT-SP registry

透运甲状腺素蛋白淀粉样变性心肌病患者中房颤的发生率及其相关因素:来自多中心REACT-SP登记研究的见解

2025-06-010
PRE
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors

口服iptacopan单药治疗阵发性夜间血红蛋白尿症:来自在抗C5治疗患者中进行的开放标签、随机、III期APPLY-PNH试验和既往未经补体抑制剂治疗的患者的开放标签、单臂、III期APPOINT-PNH试验的最终48周结果

2025-05-280
PRE
Comparative Efficacy and Safety of Daratumumab-Integrated Quadruple Therapy Versus Triple Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

达雷木单抗整合的四联疗法与三联疗法在移植适应证的新诊断多发性骨髓瘤中的比较疗效与安全性:一项系统评价和Meta分析

2025-05-140
PRE
Haploidentical, matched-related, and matched-unrelated hematopoietic cell transplant for acute leukemias in the early years of haploidentical transplant implementation in a developing country with a large unrelated donor registry

半相合、匹配亲属和匹配非亲属造血细胞移植在半相合移植实施早期,在一个拥有大型非亲属供者登记库的发展中国家的急性白血病中的应用

2025-04-150
OA
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates

门诊皮下注射 alemtuzumab 对于再生障碍性贫血是可行且安全的,并且与高缓解率相关。

2025-02-180
OA
Allogeneic Hematopoietic Cell Transplantation in Elderly Patients in a Latin American Country: Analysis of 11 Year of Data from the Brazilian Registry SBTMO/CIBMTR

拉丁美洲国家老年患者的异基因造血细胞移植: 来自巴西注册中心SBTMO/CIBMTR的11年数据分析

2025-02-010
PRE
Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
2025-01-210
OA
Phase III COMMODORE 2 and 1 Trials: Characterization of Breakthrough Hemolysis Events in Patients with Nocturnal (PNH) Treated with Crovalimab or Eculizumab

III期COMMODORE 2和1试验:接受克罗瓦利马布或依库珠单抗治疗的阵发性夜间血红蛋白尿症(PNH)患者突破性溶血事件的表征

BLOOD
IF23.1
2024-11-050
PRE
Hematopoietic Stem Cell Transplantation in Sickle Cell Disease, Experience of a Brazilian Private Service

镰状细胞病中的造血干细胞移植,巴西某私立机构的经验

BLOOD
IF23.1
2024-11-050
PRE
Early Versus Standard Initiation of Immunosuppressive Therapy for Graft Versus Host Disease Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation: Incidence and Severity of Cytokine Release Syndrome and Related Outcomes

亲缘半相合 allo 骨髓移植中,预防移植物抗宿主病的早期与标准免疫抑制疗法启动时间比较:细胞因子释放综合征的发生率、严重程度及相关结局

BLOOD
IF23.1
2024-11-050
PRE
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab

III期随机COMMODORE 1试验:从艾库努单抗转换治疗的阵发性夜间血红蛋白尿(PNH)患者中克罗瓦利单抗的2年安全性与有效性

BLOOD
IF23.1
2024-11-050
PRE